1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Schizophrenia	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	severe	_	_	JJ	_	_	_	_	_
5	mental	_	_	JJ	_	_	_	_	_
6	illness	_	_	NN	_	_	_	_	_
7	that	_	_	WDT	_	_	_	_	_
8	affects	_	_	VBZ	_	_	_	_	_
9	about	_	_	RB	_	_	_	_	_
10	one	_	_	CD	_	_	_	_	_
11	percent	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	world	_	_	NN	_	_	_	_	_
15	â€™s	_	_	POS	_	_	_	_	_
16	population	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	patients	_	_	NNS	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	schizophrenia	_	_	NN	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	characterized	_	_	VBN	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	cognitive	_	_	JJ	_	_	_	_	_
9	impairment	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	confusion	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	hallucinations	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	deterioration	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	social	_	_	JJ	_	_	_	_	_
18	function	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	noted	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	schizophrenia	_	_	NN	_	_	_	_	_
6	leads	_	_	VBZ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	heavy	_	_	JJ	_	_	_	_	_
10	burden	_	_	NN	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	their	_	_	PRP$	_	_	_	_	_
16	families	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	society	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Substantial	_	_	JJ	_	_	_	_	_
2	efforts	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	devoted	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	elucidating	_	_	VBG	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	pathophysiology	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	schizophrenia	_	_	NN	_	_	_	_	_
12	development	_	_	NN	_	_	_	_	_
13	from	_	_	IN	_	_	_	_	_
14	genetic	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	environmental	_	_	JJ	_	_	_	_	_
17	perspectives	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	as	_	_	RB	_	_	_	_	_
20	well	_	_	RB	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	gene-environment	_	_	NN	_	_	_	_	_
23	interactions	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Epidemiological	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	suggested	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	urban	_	_	JJ	_	_	_	_	_
7	environments	_	_	NNS	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	increase	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	risk	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	schizophrenia	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	may	_	_	MD	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	due	_	_	JJ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	exposure	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	toxic	_	_	JJ	_	_	_	_	_
25	heavy	_	_	JJ	_	_	_	_	_
26	metals	_	_	NNS	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	THMs	_	_	NNS	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	environment	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Chronic	_	_	JJ	_	_	_	_	_
2	exposure	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	THMs	_	_	NNPS	_	_	_	_	_
5	impairs	_	_	VBZ	_	_	_	_	_
6	numerous	_	_	JJ	_	_	_	_	_
7	biological	_	_	JJ	_	_	_	_	_
8	functions	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	results	_	_	VBZ	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	series	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	health	_	_	NN	_	_	_	_	_
16	problems	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	such	_	_	JJ	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	aberrant	_	_	JJ	_	_	_	_	_
21	immunological	_	_	JJ	_	_	_	_	_
22	responses	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	neuropathological	_	_	JJ	_	_	_	_	_
25	conditions	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	reported	_	_	VBN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	THMs	_	_	NNS	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	cause	_	_	VB	_	_	_	_	_
11	oxidative	_	_	JJ	_	_	_	_	_
12	stress	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	subsequently	_	_	RB	_	_	_	_	_
15	DNA	_	_	NN	_	_	_	_	_
16	damage	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	lipid	_	_	NN	_	_	_	_	_
19	peroxidation	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	protein	_	_	NN	_	_	_	_	_
22	modification	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	which	_	_	WDT	_	_	_	_	_
25	play	_	_	VBP	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	role	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	pathogenesis	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	numerous	_	_	JJ	_	_	_	_	_
33	diseases	_	_	NNS	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	including	_	_	VBG	_	_	_	_	_
36	cancer	_	_	NN	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	diabetes	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	neurological	_	_	JJ	_	_	_	_	_
41	disorders	_	_	NNS	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	chronic	_	_	JJ	_	_	_	_	_
44	inflammation	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	THMs	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	suggested	_	_	VBN	_	_	_	_	_
4	as	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	important	_	_	JJ	_	_	_	_	_
7	risk	_	_	NN	_	_	_	_	_
8	factor	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	mental	_	_	JJ	_	_	_	_	_
11	diseases	_	_	NNS	_	_	_	_	_
12	since	_	_	IN	_	_	_	_	_
13	they	_	_	PRP	_	_	_	_	_
14	cause	_	_	VBP	_	_	_	_	_
15	neurobehavioral	_	_	JJ	_	_	_	_	_
16	alterations	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	disrupt	_	_	VB	_	_	_	_	_
19	dopamine	_	_	NN	_	_	_	_	_
20	receptors	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	arsenic	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	As	_	_	RB	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	-induced	_	_	VBN	_	_	_	_	_
9	neurotoxicity	_	_	NN	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	reported	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	cause	_	_	VB	_	_	_	_	_
15	compositional	_	_	JJ	_	_	_	_	_
16	changes	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	hyperphosphorylation	_	_	NN	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	cytoskeletal	_	_	JJ	_	_	_	_	_
22	protein	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	leading	_	_	VBG	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	disintegration	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	cytoskeletal	_	_	JJ	_	_	_	_	_
31	framework	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	causing	_	_	VBG	_	_	_	_	_
34	neurodegenerative	_	_	JJ	_	_	_	_	_
35	diseases	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	An	_	_	DT	_	_	_	_	_
2	animal	_	_	NN	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	lead	_	_	NN	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	Pb	_	_	NNP	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	environmental	_	_	JJ	_	_	_	_	_
12	toxin	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	contributed	_	_	VBD	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	pathogenesis	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	schizophrenia	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	Disrupted-in-Schizophrenia	_	_	NNP	_	_	_	_	_
23	1	_	_	CD	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	Disc1)-mutant	_	_	JJ	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	investigating	_	_	VBG	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	association	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	environmental	_	_	JJ	_	_	_	_	_
8	THM	_	_	NN	_	_	_	_	_
9	exposure	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	risk	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	schizophrenia	_	_	NN	_	_	_	_	_
15	via	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	reliable	_	_	JJ	_	_	_	_	_
18	epidemiological	_	_	JJ	_	_	_	_	_
19	study	_	_	NN	_	_	_	_	_
20	is	_	_	VBZ	_	_	_	_	_
21	worthwhile	_	_	JJ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	serum	_	_	NN	_	_	_	_	_
3	concentration	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	THMs	_	_	NNPS	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	suggested	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	act	_	_	VB	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	an	_	_	DT	_	_	_	_	_
13	internal	_	_	JJ	_	_	_	_	_
14	indicator	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	their	_	_	PRP$	_	_	_	_	_
17	intake	_	_	NN	_	_	_	_	_
18	levels	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	reflecting	_	_	VBG	_	_	_	_	_
21	exposure	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	environmental	_	_	JJ	_	_	_	_	_
24	THMs	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Changes	_	_	NNS	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	THM	_	_	NN	_	_	_	_	_
4	concentrations	_	_	NNS	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	observed	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	peripheral	_	_	JJ	_	_	_	_	_
10	tissues	_	_	NNS	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	correlated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	risk	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	schizophrenia	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	multiple	_	_	JJ	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	investigated	_	_	VBN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	association	_	_	NN	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	THMs	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	schizophrenia	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	results	_	_	NNS	_	_	_	_	_
15	remain	_	_	VBP	_	_	_	_	_
16	inconsistent	_	_	JJ	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	despite	_	_	IN	_	_	_	_	_
5	supporting	_	_	VBG	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	both	_	_	CC	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	vitro	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	vivo	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	association	_	_	NN	_	_	_	_	_
16	between	_	_	IN	_	_	_	_	_
17	Pb	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	schizophrenia	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	cross-sectional	_	_	JJ	_	_	_	_	_
23	study	_	_	NN	_	_	_	_	_
24	among	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	Chinese	_	_	JJ	_	_	_	_	_
27	population	_	_	NN	_	_	_	_	_
28	showed	_	_	VBD	_	_	_	_	_
29	no	_	_	DT	_	_	_	_	_
30	significant	_	_	JJ	_	_	_	_	_
31	difference	_	_	NN	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	concentration	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	Pb	_	_	NN	_	_	_	_	_
37	between	_	_	IN	_	_	_	_	_
38	patients	_	_	NNS	_	_	_	_	_
39	with	_	_	IN	_	_	_	_	_
40	schizophrenia	_	_	NN	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	healthy	_	_	JJ	_	_	_	_	_
43	controls	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	another	_	_	DT	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	applying	_	_	VBG	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	very	_	_	RB	_	_	_	_	_
8	similar	_	_	JJ	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	design	_	_	NN	_	_	_	_	_
11	towards	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	same	_	_	JJ	_	_	_	_	_
14	sampling	_	_	NN	_	_	_	_	_
15	region	_	_	NN	_	_	_	_	_
16	resulted	_	_	VBD	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	significant	_	_	JJ	_	_	_	_	_
20	association	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	reason	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	divergence	_	_	NN	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	related	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	choice	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	population	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	such	_	_	JJ	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	whether	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	schizophrenic	_	_	JJ	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	have	_	_	VBP	_	_	_	_	_
23	received	_	_	VBN	_	_	_	_	_
24	antipsychotics	_	_	NNS	_	_	_	_	_
25	drug	_	_	NN	_	_	_	_	_
26	during	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	time	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	study	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	compared	_	_	VBN	_	_	_	_	_
6	serum	_	_	NN	_	_	_	_	_
7	cadmium	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	Cd	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	concentration	_	_	NN	_	_	_	_	_
12	between	_	_	IN	_	_	_	_	_
13	healthy	_	_	JJ	_	_	_	_	_
14	controls	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	schizophrenia	_	_	NN	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	or	_	_	CC	_	_	_	_	_
20	without	_	_	IN	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	serum	_	_	NN	_	_	_	_	_
3	concentration	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	Cd	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	after	_	_	IN	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	significantly	_	_	RB	_	_	_	_	_
12	higher	_	_	JJR	_	_	_	_	_
13	than	_	_	IN	_	_	_	_	_
14	that	_	_	DT	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	healthy	_	_	JJ	_	_	_	_	_
18	controls	_	_	NNS	_	_	_	_	_
19	but	_	_	CC	_	_	_	_	_
20	no	_	_	DT	_	_	_	_	_
21	significant	_	_	JJ	_	_	_	_	_
22	change	_	_	NN	_	_	_	_	_
23	was	_	_	VBD	_	_	_	_	_
24	observed	_	_	VBN	_	_	_	_	_
25	from	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	pre-treatment	_	_	NN	_	_	_	_	_
28	patients	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	concentration	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	antimony	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	uranium	_	_	NN	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	found	_	_	VBN	_	_	_	_	_
10	significantly	_	_	RB	_	_	_	_	_
11	different	_	_	JJ	_	_	_	_	_
12	between	_	_	IN	_	_	_	_	_
13	pre-treatment	_	_	JJ	_	_	_	_	_
14	patients	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	post-treatment	_	_	JJ	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	schizophrenia	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	several	_	_	JJ	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	investigated	_	_	VBN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	association	_	_	NN	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	THMs	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	schizophrenia	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	potential	_	_	JJ	_	_	_	_	_
15	mechanisms	_	_	NNS	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	link	_	_	VB	_	_	_	_	_
19	THMs	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	schizophrenia	_	_	NN	_	_	_	_	_
22	have	_	_	VBP	_	_	_	_	_
23	not	_	_	RB	_	_	_	_	_
24	been	_	_	VBN	_	_	_	_	_
25	elucidated	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	suggested	_	_	VBN	_	_	_	_	_
5	metabolic	_	_	JJ	_	_	_	_	_
6	syndrome	_	_	NN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	risk	_	_	NN	_	_	_	_	_
10	factor	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	schizophrenia	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	attributed	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	poor	_	_	JJ	_	_	_	_	_
17	dietary	_	_	JJ	_	_	_	_	_
18	habits	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	unhealthy	_	_	JJ	_	_	_	_	_
21	lifestyle	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	physical	_	_	JJ	_	_	_	_	_
24	inactivity	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	side-effects	_	_	NNS	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	second	_	_	JJ	_	_	_	_	_
33	generation-antipsychotics	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	THMs	_	_	NNS	_	_	_	_	_
7	such	_	_	JJ	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	As	_	_	NNP	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	Pb	_	_	NNP	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	found	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	associated	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	metabolic	_	_	JJ	_	_	_	_	_
19	diseases	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	suggesting	_	_	VBG	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	role	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	abnormal	_	_	JJ	_	_	_	_	_
26	metabolisms	_	_	NNS	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	linking	_	_	VBG	_	_	_	_	_
29	THMs	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	schizophrenia	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	performed	_	_	VBD	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	case-control	_	_	JJ	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	first-episode	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	drug-naÃ¯ve	_	_	JJ	_	_	_	_	_
12	schizophrenia	_	_	NN	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	healthy	_	_	JJ	_	_	_	_	_
16	controls	_	_	NNS	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	identify	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	association	_	_	NN	_	_	_	_	_
21	between	_	_	IN	_	_	_	_	_
22	serum	_	_	NN	_	_	_	_	_
23	concentrations	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	4	_	_	CD	_	_	_	_	_
27	THMs	_	_	NNS	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	i.	_	_	FW	_	_	_	_	_
30	e.	_	_	FW	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	Cr	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	Cd	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	Pb	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	As	_	_	NNP	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	selected	_	_	VBN	_	_	_	_	_
41	as	_	_	IN	_	_	_	_	_
42	commonly	_	_	RB	_	_	_	_	_
43	surveyed	_	_	VBN	_	_	_	_	_
44	heavy	_	_	JJ	_	_	_	_	_
45	metals	_	_	NNS	_	_	_	_	_
46	in	_	_	IN	_	_	_	_	_
47	schizophrenia	_	_	NN	_	_	_	_	_
48	studies	_	_	NNS	_	_	_	_	_
49	)	_	_	-RRB-	_	_	_	_	_
50	and	_	_	CC	_	_	_	_	_
51	the	_	_	DT	_	_	_	_	_
52	risk	_	_	NN	_	_	_	_	_
53	of	_	_	IN	_	_	_	_	_
54	schizophrenia	_	_	NN	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	correlations	_	_	NNS	_	_	_	_	_
3	between	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	4	_	_	CD	_	_	_	_	_
6	THMs	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	multiple	_	_	JJ	_	_	_	_	_
9	metabolic	_	_	JJ	_	_	_	_	_
10	biomarkers	_	_	NNS	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	tested	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	explore	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	potential	_	_	JJ	_	_	_	_	_
18	metabolisms	_	_	NNS	_	_	_	_	_
19	associated	_	_	VBN	_	_	_	_	_
20	between	_	_	IN	_	_	_	_	_
21	these	_	_	DT	_	_	_	_	_
22	THMs	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	schizophrenia	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	meta-analysis	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	conducted	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	comprehensively	_	_	RB	_	_	_	_	_
8	summarize	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	association	_	_	NN	_	_	_	_	_
11	between	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	4	_	_	CD	_	_	_	_	_
14	individual	_	_	JJ	_	_	_	_	_
15	THMs	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	risk	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	schizophrenia	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_

